Preemptive oxycodone is superior to equal dose of sufentanil to reduce visceral pain and inflammatory markers after surgery: a randomized controlled trail.
Abstract | BACKGROUND: METHODS: RESULTS: Twenty patients were recruited in each group. Numerical rating scale (NRS) of visceral pain in the oxycodone group at 2 h when resting (0.5(0,2.75) vs 3(2,4), P = 0.008) and moving (0.5(0,3) vs 3(2.25,4), P = 0.015) and 4 h when moving (2(0,3) vs 3(0,4.75), P = 0.043) after surgery were significantly lower than the sufentanil group. Serum concentrations of TNF-α at 6 h (38.68 ± 10.49 vs 73.02 ± 16.27, P<0.001) and 24 h (43.12 ± 8.40 vs 74.00 ± 21.30, P<0.001) in the oxycodone group were lower than the sufentanil group. CONCLUSIONS: TRIAL REGISTRATION: Clinical trials registration number: ChiCTR-IOR-17013738 http://www.chictr.org.cn/showproj.aspx?proj=17346 . Date of registration: 6th December 2017.
|
Authors | Yi An, Lei Zhao, Tianlong Wang, Jiapeng Huang, Wei Xiao, Ping Wang, Lixia Li, Zhongjia Li, Xiaoxu Chen |
Journal | BMC anesthesiology
(BMC Anesthesiol)
Vol. 19
Issue 1
Pg. 96
(06 11 2019)
ISSN: 1471-2253 [Electronic] England |
PMID | 31185942
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics, Opioid
- Inflammation Mediators
- Sufentanil
- Oxycodone
|
Topics |
- Adult
- Analgesics, Opioid
(administration & dosage)
- Cholecystectomy, Laparoscopic
(adverse effects, trends)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Inflammation Mediators
(antagonists & inhibitors, blood)
- Male
- Middle Aged
- Oxycodone
(administration & dosage)
- Pain, Postoperative
(blood, drug therapy, etiology)
- Prospective Studies
- Sufentanil
(administration & dosage)
- Visceral Pain
(blood, drug therapy, etiology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|